FDA approves Lipsovir for treatment of cold sores

Medivir has received approval to market Lipsovir (hydrocortisone and acyclovir, cream) for the topical treatment of cold sores in patients ≥12 years of age.  Lipsovir is indicated for early treatment of recurrent herpes labialis (cold sores) to decreases the risk of cold sores, and to shorten the healing time for those cold sores which are not prevented.

For more information visit www.medivir.se.